Chamberlain, Jayne L. http://orcid.org/0000-0001-5699-9595
Huda, Saif
Whittam, Daniel H.
Matiello, Marcelo
Morgan, B. Paul
Jacob, Anu
Article History
Received: 31 May 2019
Revised: 2 August 2019
Accepted: 5 August 2019
First Online: 3 September 2019
Change Date: 15 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00415-021-10896-w
Change Date: 17 October 2019
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00415-019-09568-7
Compliance with ethical standards
:
: AJ: Principal Investigator for the ECU301 and ECU302 trials on Eculizumab in neuromyelitis optica in the UK. AJ has also received research grants from Alexion Pharmaceuticals, Biogen Idec and speaker fees from Biogeb, Chugai, Sanofi-Genzyme and Terumo-BCT. MM: Adboard consulting for Alexion Pharmaceuticals. JC, SH, DH and BPM have no conflicts of interest.
: This is a review article and does not involve any animal or human research.